Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)

4 Sep 2019

Company on Track for Data Read Out by End of 2019

Leuven, Belgium, 4 September 2019 – 7.30 AM CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces the completion of enrollment of patients in a Phase 1 trial with THR-687.

The open-label, multicenter, dose escalation Phase 1 study is evaluating the safety of a single intravitreal injection of escalating dose levels (3) of THR-687 for the treatment of patients with diabetic macula edema (DME).  A total of 12 patients with DME have been enrolled into the US-based study ( NCT03666923).

THR-687 is a novel pan-RGD integrin antagonist currently being developed as a potential treatment for patients with diabetic eye disease. Preclinical studies have demonstrated that THR-687 is able to target multiple aspects of retinal vascular disease such as vessel leakage, inflammation, and neovascularization.

Results from this Phase 1 study are expected by end of 2019.

Patrik De Haes, MD, CEO of Oxurion nv, commentsThe completion of patient recruitment means that we are on track to announce the results from this study before the end of 2019. Following the recent positive Phase 1 results with THR-149, we are looking forward to the first clinical data read-out with THR-687, the second VEGF independent molecule and pathway in our innovative DME focused pipeline.”  

Press release attachment: